X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
VT-X7, (Vancomycin Hydrochloride), a drug/device combination product that locally delivers, via irrigation, highly targeted antibiotic therapy to the hip or knee during an accelerated seven-day interstage period of a two-stage exchange arthroplasty.
Lead Product(s): Vancomycin Hydrochloride,Tobramycin
Therapeutic Area: Musculoskeletal Product Name: VT-X7
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2022
Details:
Tobradex® Ophthalmic Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.
Lead Product(s): Tobramycin,Dexamethasone
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2022
Details:
Tobramycin (generic to Tobradex) Ophthalmic Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.
Lead Product(s): Tobramycin,Dexamethasone
Therapeutic Area: Infections and Infectious Diseases Product Name: Tobramycin / Dexamethasone-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2022
Details:
The proceeds will enable Osteal to continue development of its integrated technologies, advance the clinical development of its lead candidate, VT-X7 for treatment of periprosthetic joint infection and fund new research programs.
Lead Product(s): Vancomycin Hydrochloride,Tobramycin
Therapeutic Area: Infections and Infectious Diseases Product Name: VT-X7
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: HM Capital
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 08, 2022
Details:
Dexamethasone & Tobramycin Ophthalmic Suspension 0.3%/0.1% is generic version of TobraDex, which is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or risk of it exists.
Lead Product(s): Dexamethasone,Tobramycin
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2021
Details:
Sonoran's lead product SBG003 (tobramycin and vancomycin hydrogel) has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. Food & Drug Administration (FDA) for prevention of post-abdominal surgical site infection.
Lead Product(s): Tobramycin,Vancomycin Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: SBG003
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
